Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Alkermes Plc (ALKS): Insiders Aren’t Crazy About It

Page 1 of 2

Alkermes Plc (NASDAQ:ALKS) investors should be aware of a decrease in support from the world’s most elite money managers of late.

In today’s marketplace, there are many indicators market participants can use to analyze publicly traded companies. A pair of the most innovative are hedge fund and insider trading sentiment. At Insider Monkey, our research analyses have shown that, historically, those who follow the best picks of the elite hedge fund managers can beat the market by a significant margin (see just how much).

Alkermes Plc (NASDAQ:ALKS)Equally as key, positive insider trading sentiment is a second way to parse down the investments you’re interested in. Obviously, there are plenty of reasons for an upper level exec to downsize shares of his or her company, but just one, very clear reason why they would buy. Several academic studies have demonstrated the market-beating potential of this method if you know what to do (learn more here).

With these “truths” under our belt, let’s take a look at the key action regarding Alkermes Plc (NASDAQ:ALKS).

How are hedge funds trading Alkermes Plc (NASDAQ:ALKS)?

At the end of the first quarter, a total of 15 of the hedge funds we track were bullish in this stock, a change of 0% from one quarter earlier. With the smart money’s positions undergoing their usual ebb and flow, there exists a select group of notable hedge fund managers who were increasing their holdings significantly.

Of the funds we track, Kevin Kotler’s Broadfin Capital had the most valuable position in Alkermes Plc (NASDAQ:ALKS), worth close to $31.9 million, comprising 7% of its total 13F portfolio. Sitting at the No. 2 spot is Xerion, managed by Daniel Arbess, which held a $9.2 million position; 0.5% of its 13F portfolio is allocated to the stock. Remaining hedgies that hold long positions include Israel Englander’s Millennium Management, and Peter Rathjens, Bruce Clarke and John Campbell’s Arrowstreet Capital.

Due to the fact that Alkermes Plc (NASDAQ:ALKS) has experienced bearish sentiment from the aggregate hedge fund industry, logic holds that there were a few hedgies who were dropping their positions entirely last quarter. At the top of the heap, Phill Gross and Robert Atchinson’s Adage Capital Management said goodbye to the biggest investment of the 450+ funds we track, totaling about $8 million in stock.. Richard Schimel’s fund, Diamondback Capital, also said goodbye to its call options., about $2 million worth. These bearish behaviors are intriguing to say the least, as aggregate hedge fund interest stayed the same (this is a bearish signal in our experience).

Insider trading activity in Alkermes Plc (NASDAQ:ALKS)

Insider buying is most useful when the company in focus has seen transactions within the past 180 days. Over the latest 180-day time period, Alkermes Plc (NASDAQ:ALKS) has experienced zero unique insiders buying, and 10 insider sales (see the details of insider trades here).

Let’s also examine hedge fund and insider activity in other stocks similar to Alkermes Plc (NASDAQ:ALKS). These stocks are Delcath Systems, Inc. (NASDAQ:DCTH), Petmed Express Inc (NASDAQ:PETS), Valeant Pharmaceuticals Intl Inc (NYSE:VRX), Elan Corporation, plc (ADR) (NYSE:ELN), and Hospira, Inc. (NYSE:HSP). All of these stocks are in the drug delivery industry and their market caps are closest to ALKS’s market cap.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!